Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

This study has been completed.

Sponsor:

Collaborators:

Genentech

Celgene Corporation

Information provided by (Responsible Party):

Accelerated Community Oncology Research Network

ClinicalTrials.gov Identifier:

NCT00407563

First received: December 4, 2006

Last updated: March 8, 2012

Last verified: March 2012

History of Changes

Results First Received: September 28, 2011

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Conditions:	Epithelial Ovarian Cancer Primary Peritoneal Carcinoma
Interventions:	Drug: Bevacizumab Drug: Abraxane

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
9 community oncology research sites across the US within the ACORN network participated in this study. Enrollment started in January 2007 and was completed in December 2008.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Informed consent was obtained from all subjects. All subjects underwent screening procedures to verify eligibility.

Reporting Groups

	Description
Bevacizumab and Abraxane	All subjects received treatment with bevacizumab and Abraxane. Bevacizumab will be given via IV infusion at 10 mg/kg given on days 1 and 15 of a 28-day cycle. Abraxane will be given via IV infusion at 100 mg/m^2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Participant Flow: Overall Study

	Bevacizumab and Abraxane
STARTED	48
COMPLETED	47 ^[1]
NOT COMPLETED	1
Patient continues on treatment	1

[1]	One patient remains on study treatment.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Bevacizumab and Abraxane	All subjects received treatment with bevacizumab and Abraxane. Bevacizumab will be given via IV infusion at 10 mg/kg given on days 1 and 15 of a 28-day cycle. Abraxane will be given via IV infusion at 100 mg/m^2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Baseline Measures

	Bevacizumab and Abraxane
Number of Participants [units: participants]	48
Age [units: participants]
<=18 years	0
Between 18 and 65 years	26
>=65 years	22
Age [units: years] Mean ± Standard Deviation	61.6 ± 10.22
Gender [units: participants]
Female	48
Male	0
Region of Enrollment [units: participants]
United States	48

Outcome Measures

Show All Outcome Measures

1. Primary:

6-month Progression-Free Rate [ Time Frame: 6 months after initiation of study treatment ]

Show Outcome Measure 1

2. Secondary:

Best Overall Response [ Time Frame: Radiologic imaging was repeated after every 3 cycles (about every 12 weeks) during study treatment, up to 31 months. ]

Show Outcome Measure 2

3. Secondary:

Overall Survival [ Time Frame: Overall survival is defined as the time from treatment start until death from any cause, assessed up to 40 months. ]

Show Outcome Measure 3

4. Secondary:

Progression-free Survival (PFS) [ Time Frame: PFS was measured from day 1 of treatment until time of progression (assessed every 12 weeks) or death, whichever came first, assessed up to 30 months. ]

Show Outcome Measure 4

5. Secondary:

Best Overall Response at Six Months [ Time Frame: Assessed over 6 months of study treatment ]

Show Outcome Measure 5

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Hide Other Adverse Events

Time Frame	Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment, up to 32 months.
Additional Description	Systematic Assessment - subjects were assessed for adverse events weekly by either the research coordinator, treating physician, or other appropriate sub-investigator.

Frequency Threshold

Threshold above which other adverse events are reported	0%

Reporting Groups

	Description
Bevacizumab and Abraxane	All subjects received treatment with bevacizumab and Abraxane. Bevacizumab will be given via IV infusion at 10 mg/kg given on days 1 and 15 of a 28-day cycle. Abraxane will be given via IV infusion at 100 mg/m^2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Other Adverse Events

	Bevacizumab and Abraxane
Total, other (not including serious) adverse events
# participants affected / at risk	47/48
Blood and lymphatic system disorders
Anemia ^{† 1}
# participants affected / at risk	10/48 (20.83%)
Leukopenia ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Lymphadenopathy ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Lymphopenia ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Neutropenia ^{† 1}
# participants affected / at risk	14/48 (29.17%)
Thrombocytopenia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Cardiac disorders
Palpitations ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Ear and labyrinth disorders
External ear pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Tinnitus ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Eye disorders
Blepharitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Cataract ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Diplopia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Dry eye ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Erythema of eyelid ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Eye hemorrhage ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Lacrimation increased ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Photopsia ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Vision blurred ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Gastrointestinal disorders
Abdominal distension ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Abdominal pain ^{† 1}
# participants affected / at risk	11/48 (22.92%)
Abdominal pain lower ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Abdominal pain upper ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Ascites ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Colitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Constipation ^{† 1}
# participants affected / at risk	16/48 (33.33%)
Diarrhea ^{† 1}
# participants affected / at risk	16/48 (33.33%)
Dry mouth ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Dyspepsia ^{† 1}
# participants affected / at risk	5/48 (10.42%)
Feces hard ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Gingival pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Glossodynia ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Hemorrhoids ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Nausea ^{† 1}
# participants affected / at risk	18/48 (37.50%)
Oral pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Paresthesia oral ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Peritoneal and retroperitoneal disorders ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Proctalgia ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Rectal hemorrhage ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Reflux gastritis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Small intestinal obstruction ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sore mouth ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Stomatitis ^{† 1}
# participants affected / at risk	11/48 (22.92%)
Toothache ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Vomiting ^{† 1}
# participants affected / at risk	14/48 (29.17%)
General disorders
Asthenia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Catheter site inflammation ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Chest pain ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Chills ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Fatigue ^{† 1}
# participants affected / at risk	37/48 (77.08%)
Inflammation ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Influenza like illness ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Injection site reaction ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Local swelling ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Localized edema ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Malaise ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nodule ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Edema peripheral ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Pain ^{† 1}
# participants affected / at risk	5/48 (10.42%)
Pyrexia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hepatobiliary disorders
Hepatic pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hepatomegaly ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Immune system disorders
Hypersensitivity ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Multiple allergies ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Infections and infestations
Bronchitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Candidiasis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Catheter site infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Cellulitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Device related infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Fungal infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Gastroenteritis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hand-foot-and-mouth disease ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Laryngitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Localized infection ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Nasopharyngitis ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Oral herpes ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Pharyngitis streptococcal ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Postpoperative wound infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Rhinitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sepsis syndrome ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sialoadenitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sinusitis ^{† 1}
# participants affected / at risk	7/48 (14.58%)
Streptococcal infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Tooth infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Upper respiratory tract infection ^{† 1}
# participants affected / at risk	8/48 (16.67%)
Urinary tract infection ^{† 1}
# participants affected / at risk	11/48 (22.92%)
Vaginal infection ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Vaginitis bacterial ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Wound infection ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Injury, poisoning and procedural complications
Chest injury ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Contusion ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Joint sprain ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Post procedural hemorrhage ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Postoperative ileus ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Procedural pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Procedural site reaction ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Skin laceration ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Investigations
Aspartate aminotransferase increased ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Blood creatinine increased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Blood lactate dehydrogenase increased ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Blood pressure increased ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Blood thyroid stimulating hormone increased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Body temperature increased ^{† 1}
# participants affected / at risk	4/48 (8.33%)
C-reactive protein increased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
CD4 lymphocytes increased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Forced expiratory volume ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hematocrit decreased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hemoglobin decreased ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Monoctye count increased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Neutrophil count decreased ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Parasite stool test positive ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Platelet count decreased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Red blood cell count decreased ^{† 1}
# participants affected / at risk	1/48 (2.08%)
White blood cell count decreased ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Metabolism and nutrition disorders
Decreased appetite ^{† 1}
# participants affected / at risk	8/48 (16.67%)
Dehydration ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Fluid retention ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hypercalcemia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hyperglycemia ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Hyperkalemia ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Hypermagnesemia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hypernatremia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hyperphosphatemia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hypoglycemia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hypokalemia ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Hypomagnesemia ^{† 1}
# participants affected / at risk	6/48 (12.50%)
Hypophosphatemia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Weight loss poor ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Musculoskeletal and connective tissue disorders
Arthralgia ^{† 1}
# participants affected / at risk	14/48 (29.17%)
Arthritis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Back pain ^{† 1}
# participants affected / at risk	5/48 (10.42%)
Flank pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Foot fracture ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Groin pain ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Joint stiffness ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Joint swelling ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Muscle spasms ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Muscular weakness ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Musculoskeletal discomfort ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Musculoskeletal pain ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Myalgia ^{† 1}
# participants affected / at risk	6/48 (12.50%)
Osteoporosis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Pain in extremity ^{† 1}
# participants affected / at risk	9/48 (18.75%)
Plantar fasciitis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Temporomandibular joint syndrome ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumor benign ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nervous system disorders
Dizziness ^{† 1}
# participants affected / at risk	5/48 (10.42%)
Dysgeusia ^{† 1}
# participants affected / at risk	7/48 (14.58%)
Encephalopathy ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Headache ^{† 1}
# participants affected / at risk	12/48 (25.00%)
Hypoesthesia ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Memory impairment ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Nerve compression ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Neuralgia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Neuropathy peripheral ^{† 1}
# participants affected / at risk	15/48 (31.25%)
Paresthesia ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sciatica ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sinus headache ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Psychiatric disorders
Anxiety ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Depression ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Disturbance in attention ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Insomnia ^{† 1}
# participants affected / at risk	9/48 (18.75%)
Mood altered ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nightmare ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Renal and urinary disorders
Dysuria ^{† 1}
# participants affected / at risk	6/48 (12.50%)
Hematuria ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Micturition urgency ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Proteinuria ^{† 1}
# participants affected / at risk	6/48 (12.50%)
Urethral pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Reproductive system and breast disorders
Breast pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Edema genital ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Pelvic pain ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sexual dysfunction ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Vaginal discharge ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Vaginal hemorrhage ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Vulvovaginal dryness ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Vulvovaginal pruritis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Respiratory, thoracic and mediastinal disorders
Asthma ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Cough ^{† 1}
# participants affected / at risk	11/48 (22.92%)
Dysphonia ^{† 1}
# participants affected / at risk	9/48 (18.75%)
Dyspnea ^{† 1}
# participants affected / at risk	10/48 (20.83%)
Dyspnea exertional ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Epistaxis ^{† 1}
# participants affected / at risk	23/48 (47.92%)
Hemoptysis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nasal congestion ^{† 1}
# participants affected / at risk	3/48 (6.25%)
Oropharyngeal pain ^{† 1}
# participants affected / at risk	5/48 (10.42%)
Paranasal sinus discomfort ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Pneumothorax ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Postnasal drip ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Respiratory tract congestion ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Rhinitis allergic ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Rhinorrhea ^{† 1}
# participants affected / at risk	6/48 (12.50%)
Sinus congestion ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Sinus disorder ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Sinus disorder, NOS ^{† 1}
# participants affected / at risk	2/48 (4.17%)
Skin and subcutaneous tissue disorders
Acne ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Alopecia ^{† 1}
# participants affected / at risk	15/48 (31.25%)
Blister ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Dermatitis acneiform ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Dry skin ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nail discoloration ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Nail disorder ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Onychomadesis ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Pruritus ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Rash ^{† 1}
# participants affected / at risk	4/48 (8.33%)
Skin discoloration ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Skin disorder ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Skin hyperpigmentation ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Umbilical hemorrhage ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Surgical and medical procedures
Ileostomy ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Tooth extraction ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Vascular disorders
Flushing ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hot flush ^{† 1}
# participants affected / at risk	1/48 (2.08%)
Hypertension ^{† 1}
# participants affected / at risk	10/48 (20.83%)
Hypotension ^{† 1}
# participants affected / at risk	3/48 (6.25%)

†	Events were collected by systematic assessment
1	Term from vocabulary, CTCAE (3.0)

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Proposed publication must be submitted to Funder at least 60 days prior to the submission for publication. If Funder requests in writing, the proposed publication may be held for an additional 90 days.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Vice President of Scientific Affairs
Organization: Accelerated Community Oncology Research Network, Inc.
phone: 901-435-5570
e-mail: mwalker@acorncro.com

No publications provided by Accelerated Community Oncology Research Network

Publications automatically indexed to this study:

Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol. 2013 Feb;128(2):221-8. doi: 10.1016/j.ygyno.2012.08.039. Epub 2012 Sep 5.

Responsible Party:	Accelerated Community Oncology Research Network
ClinicalTrials.gov Identifier:	NCT00407563 History of Changes
Other Study ID Numbers:	ACORN ALSSOPR0501
Study First Received:	December 4, 2006
Results First Received:	September 28, 2011
Last Updated:	March 8, 2012
Health Authority:	United States: Institutional Review Board

To Top